Rockland Trust Co. Sells 472 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Rockland Trust Co. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,508 shares of the medical research company’s stock after selling 472 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.3% of Rockland Trust Co.’s portfolio, making the stock its 24th largest position. Rockland Trust Co.’s holdings in Thermo Fisher Scientific were worth $14,572,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Ellevest Inc. grew its position in Thermo Fisher Scientific by 137.5% during the second quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock valued at $28,000 after buying an additional 55 shares during the period. American National Bank bought a new position in Thermo Fisher Scientific during the third quarter valued at about $29,000. Massey Quick Simon & CO. LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at about $30,000. Redhawk Wealth Advisors Inc. bought a new position in Thermo Fisher Scientific during the second quarter valued at about $31,000. Finally, Prestige Wealth Management Group LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at about $32,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.

NYSE TMO traded up $6.26 during trading on Friday, hitting $286.92. 29,203 shares of the company’s stock traded hands, compared to its average volume of 1,624,854. Thermo Fisher Scientific Inc. has a 12-month low of $208.34 and a 12-month high of $305.45. The stock has a market capitalization of $108.90 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 1.78 and a beta of 1.13. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The business has a 50 day moving average of $287.07 and a 200-day moving average of $280.74.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. During the same period in the prior year, the firm posted $2.75 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current year.

TMO has been the topic of several recent research reports. ValuEngine downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group reaffirmed a “buy” rating and set a $310.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Barclays set a $330.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Needham & Company LLC upped their price objective on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $305.27.

In other news, CEO Marc N. Casper sold 2,271 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the sale, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at $84,483,596. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the sale, the director now directly owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,104 shares of company stock worth $15,418,539. Insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Market Indexes

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit